Form 4: IMMUNIC CFO Glenn Whaley Granted 1.96 Million Stock Appreciation Rights

IMMUNIC, INC.'s Chief Financial Officer, Glenn Whaley, was granted 1.96 million Stock Appreciation Rights with an exercise price of $0.77, exercisable from August 1, 2026, subject to specific conditions.

Summary

• Glenn Whaley, Chief Financial Officer of IMMUNIC, INC. (IMUX), was granted a total of 1,960,000 Stock Appreciation Rights (SARs) on July 16, 2025.
• The SARs have an exercise price of $0.77 per SAR.
• These SARs are intended to be settled for shares of the Issuer's common stock, contingent on obtaining stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to provide sufficient shares.
• The SARs become exercisable starting August 1, 2026, and expire on July 16, 2035.
• Exercisability is subject to several conditions, including the exercise of the Issuer's series A and B purchase warrants, and the issuance of common stock or pre-funded warrants related to the second and third tranches of the January 4, 2024 private placement.

Sentiment

Score: 6

Explanation: The grant of SARs is a positive for executive incentives, aligning management with shareholder interests. However, the conditional nature of exercisability and the need for stockholder approval for equity settlement introduce some uncertainty, preventing a higher score. It's a standard compensation event with forward-looking conditions.

Positives

• Grant of Stock Appreciation Rights aligns the Chief Financial Officer's incentives with shareholder value creation.
• The SARs have a long expiration date of July 16, 2035, providing a long-term incentive.
• The exercise price of $0.77 is relatively low, suggesting potential for significant upside if the stock price increases.

Negatives

• The exercisability of the SARs is subject to multiple conditions, including the exercise of warrants and completion of private placement tranches, which introduces uncertainty.
• Settlement in common stock is contingent on stockholder approval to amend the equity incentive plan, which may not be granted.

Risks

• The exercisability of the SARs is conditional on the exercise of series A and B purchase warrants, which may not occur.
• Exercisability is also dependent on the successful completion and issuance of shares/warrants for the second and third tranches of the January 2024 private placement, which carries execution risk.
• The intention to settle SARs in common stock is subject to stockholder approval to amend the 2019 Omnibus Equity Incentive Plan; failure to obtain approval could result in cash settlement, impacting the company's cash position.

Future Outlook

The exercisability of the granted Stock Appreciation Rights is tied to future events, including the exercise of series A and B purchase warrants and the successful completion of the second and third tranches of the January 2024 private placement. The company intends to settle these SARs in common stock, pending future stockholder approval to amend its 2019 Omnibus Equity Incentive Plan.

Industry Context

This Form 4 filing details an executive compensation grant, which is a standard practice in publicly traded companies across all industries, including the biotechnology/pharmaceutical sector where IMMUNIC, INC. operates. Such grants are designed to align management's long-term interests with shareholder value creation. The specific conditions tied to warrant exercises and private placement tranches reflect ongoing capital raising and financing activities common in the biotech industry for funding research and development.

Corporate Governance

Related Party Transactions

• Grant of 1,960,000 Stock Appreciation Rights to Glenn Whaley, the Chief Financial Officer of IMMUNIC, INC., on July 16, 2025.

Stakeholder Impact

• Shareholders: Potential dilution if SARs are settled in shares and stockholder approval for the plan amendment is granted. Alignment of CFO's incentives with shareholder value.
• Employees: No direct impact mentioned for general employees, but the equity incentive plan amendment could affect future grants.
• Creditors: Potential impact on cash flow if SARs are ultimately cash-settled due to lack of stockholder approval for equity settlement.

Next Steps

• Obtain stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan to provide sufficient shares for SAR settlement.
• Exercise of the Issuer's series A purchase warrants by holders.
• Exercise of the Issuer's series B purchase warrants by holders.
• Issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the January 2024 private placement.
• Issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.
• SARs become exercisable starting August 1, 2026, subject to conditions.

Key Dates

Keywords

IMMUNIC, IMUX, Stock Appreciation Rights, SARs, Executive Compensation, Glenn Whaley, CFO, SEC Form 4, Equity Incentive Plan, Private Placement, Warrants